Effect of Galantamine on Smoking Abstinence

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

October 31, 2013

Conditions
Nicotine Addiction
Interventions
DRUG

Galantamine ER

"The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease. The dosing regimen, which follows FDA-approved guidelines, will be an initial 4 weeks of drug run-up at the lowest 8mg daily dose, followed by an additional one week of drug run-up at the higher dose of 16mg daily.~Participants will continue to take the 16mg daily during the 7-day quit week, for a total of 6 weeks of treatment with galantamine-ER."

Trial Locations (1)

19104

Center for Interdisciplinary Research on Nicotine Addiction, School of Medicine, University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT01548638 - Effect of Galantamine on Smoking Abstinence | Biotech Hunter | Biotech Hunter